Mark S. Shaefer
Triangle(US)Windsor Dermatology(US)Jiangsu Hengrui Medicine (China)(CN)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV-related health complications and treatments, Renal Transplantation Outcomes and Treatments
Most-Cited Works
- → High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients(2008)429 cited
- → Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study(2020)346 cited
- → The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial(2006)341 cited
- → Pharmacokinetics of tacrolimus in liver transplant patients*(1995)239 cited
- → Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment(2009)217 cited
- → Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects